468 related articles for article (PubMed ID: 17210763)
1. Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity.
Liu S; Rowe PS; Vierthaler L; Zhou J; Quarles LD
J Endocrinol; 2007 Jan; 192(1):261-7. PubMed ID: 17210763
[TBL] [Abstract][Full Text] [Related]
2. Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP.
Martin A; David V; Laurence JS; Schwarz PM; Lafer EM; Hedge AM; Rowe PS
Endocrinology; 2008 Apr; 149(4):1757-72. PubMed ID: 18162525
[TBL] [Abstract][Full Text] [Related]
3. Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway.
Rowe PS
Crit Rev Eukaryot Gene Expr; 2012; 22(1):61-86. PubMed ID: 22339660
[TBL] [Abstract][Full Text] [Related]
4. MEPE-ASARM peptides control extracellular matrix mineralization by binding to hydroxyapatite: an inhibition regulated by PHEX cleavage of ASARM.
Addison WN; Nakano Y; Loisel T; Crine P; McKee MD
J Bone Miner Res; 2008 Oct; 23(10):1638-49. PubMed ID: 18597632
[TBL] [Abstract][Full Text] [Related]
5. Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP).
Rowe PS; Garrett IR; Schwarz PM; Carnes DL; Lafer EM; Mundy GR; Gutierrez GE
Bone; 2005 Jan; 36(1):33-46. PubMed ID: 15664000
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation-dependent inhibition of mineralization by osteopontin ASARM peptides is regulated by PHEX cleavage.
Addison WN; Masica DL; Gray JJ; McKee MD
J Bone Miner Res; 2010 Apr; 25(4):695-705. PubMed ID: 19775205
[TBL] [Abstract][Full Text] [Related]
7. Abnormal presence of the matrix extracellular phosphoglycoprotein-derived acidic serine- and aspartate-rich motif peptide in human hypophosphatemic dentin.
Boukpessi T; Gaucher C; Léger T; Salmon B; Le Faouder J; Willig C; Rowe PS; Garabédian M; Meilhac O; Chaussain C
Am J Pathol; 2010 Aug; 177(2):803-12. PubMed ID: 20581062
[TBL] [Abstract][Full Text] [Related]
8. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization.
Quarles LD
Am J Physiol Endocrinol Metab; 2003 Jul; 285(1):E1-9. PubMed ID: 12791601
[TBL] [Abstract][Full Text] [Related]
9. MEPE-derived ASARM peptide inhibits odontogenic differentiation of dental pulp stem cells and impairs mineralization in tooth models of X-linked hypophosphatemia.
Salmon B; Bardet C; Khaddam M; Naji J; Coyac BR; Baroukh B; Letourneur F; Lesieur J; Decup F; Le Denmat D; Nicoletti A; Poliard A; Rowe PS; Huet E; Vital SO; Linglart A; McKee MD; Chaussain C
PLoS One; 2013; 8(2):e56749. PubMed ID: 23451077
[TBL] [Abstract][Full Text] [Related]
10. Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice.
Liu S; Tang W; Zhou J; Vierthaler L; Quarles LD
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1636-44. PubMed ID: 17848631
[TBL] [Abstract][Full Text] [Related]
11. The chicken or the egg: PHEX, FGF23 and SIBLINGs unscrambled.
Rowe PS
Cell Biochem Funct; 2012 Jul; 30(5):355-75. PubMed ID: 22573484
[TBL] [Abstract][Full Text] [Related]
12. ASARM peptides: PHEX-dependent and -independent regulation of serum phosphate.
David V; Martin A; Hedge AM; Drezner MK; Rowe PS
Am J Physiol Renal Physiol; 2011 Mar; 300(3):F783-91. PubMed ID: 21177780
[TBL] [Abstract][Full Text] [Related]
13. SPR4-peptide alters bone metabolism of normal and HYP mice.
Zelenchuk LV; Hedge AM; Rowe PS
Bone; 2015 Mar; 72():23-33. PubMed ID: 25460577
[TBL] [Abstract][Full Text] [Related]
14. MEPE has the properties of an osteoblastic phosphatonin and minhibin.
Rowe PS; Kumagai Y; Gutierrez G; Garrett IR; Blacher R; Rosen D; Cundy J; Navvab S; Chen D; Drezner MK; Quarles LD; Mundy GR
Bone; 2004 Feb; 34(2):303-19. PubMed ID: 14962809
[TBL] [Abstract][Full Text] [Related]
15. The wrickkened pathways of FGF23, MEPE and PHEX.
Rowe PS
Crit Rev Oral Biol Med; 2004 Sep; 15(5):264-81. PubMed ID: 15470265
[TBL] [Abstract][Full Text] [Related]
16. Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism.
Atkins GJ; Rowe PS; Lim HP; Welldon KJ; Ormsby R; Wijenayaka AR; Zelenchuk L; Evdokiou A; Findlay DM
J Bone Miner Res; 2011 Jul; 26(7):1425-36. PubMed ID: 21312267
[TBL] [Abstract][Full Text] [Related]
17. Active sites of human MEPE-ASARM regulating bone matrix mineralization.
Minamizaki T; Sakurai K; Hayashi I; Toshishige M; Yoshioka H; Kozai K; Yoshiko Y
Mol Cell Endocrinol; 2020 Nov; 517():110931. PubMed ID: 32712387
[TBL] [Abstract][Full Text] [Related]
18. Age dependent regulation of bone-mass and renal function by the MEPE ASARM-motif.
Zelenchuk LV; Hedge AM; Rowe PS
Bone; 2015 Oct; 79():131-42. PubMed ID: 26051469
[TBL] [Abstract][Full Text] [Related]
19. Pathogenic role of Fgf23 in Hyp mice.
Liu S; Zhou J; Tang W; Jiang X; Rowe DW; Quarles LD
Am J Physiol Endocrinol Metab; 2006 Jul; 291(1):E38-49. PubMed ID: 16449303
[TBL] [Abstract][Full Text] [Related]
20. Do ASARM peptides play a role in nephrogenic systemic fibrosis?
Rowe PS; Zelenchuk LV; Laurence JS; Lee P; Brooks WM; McCarthy ET
Am J Physiol Renal Physiol; 2015 Nov; 309(9):F764-9. PubMed ID: 26336161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]